Cryosite Limited · ASX:CTE
Cryosite — Bell Potter Healthcare Conference 2026
9 slides from Cryosite's conference presentation, November 2026
Slide 1: Corporate Presentation - Bell Potter Healthcare Conference 2026
rsonal use only Bell Potter Healthcare Conference 2026 Corporate Presentation 17 November 2026 · ASX: CTE
Slide 2: Disclaimer
Disclaimer rsonal use only The following disclaimer applies to this non-confidential presentation prepared by Cryosite Limited ACN 090 919 476 (Cryosite) which is dated 17 November 2026 (Presentation). By accepting or receiving this Presentation, you acknowledge and agree to the terms set out below.
Slide 3: Who we are: From cord blood to advanced therapies
WHO WE ARE From cord blood to advanced therapies rsonal use only Our Specialisation Controlled Cold Frozen Ultra-Frozen Cryogenic Cord Blood Ambient 2 to 8°C −20°C −80°C Below −150°C Cryogenic 15 to 25°C + Schedule 8 vault • Small-molecule drugs • Small-molecule drugs • Frozen vaccines • mRNA vaccin
Slide 4: Who we serve: Trusted by sponsors. Hard to replicate.
WHO WE SERVE Trusted by sponsors. Hard to replicate. rsonal use only OUR CLIENTS Big Pharma CROs Biotech Hospitals Universities R&D 11 of the Top 15 WHY THEY STAY TGA GMP 24+ years Multi-year Record EcoVadis Licensed for storage, Cryogenic track Contracts with Quality Gold, two years labelling and r
Slide 5: How we operate: Controlled custody at every step, import to returns
HOW WE OPERATE Controlled custody at every step, import to returns rsonal use only END-TO-END SERVICES Import Receive Store Label & pack Distribute Returns Continuous monitoring Redundant systems Full traceability Specialist handling 24/7 temperature Backup power and dual Every sample tracked, Train
Slide 6: Two-site platform: Footprint more than doubled
TWO-SITE PLATFORM Footprint more than doubled: 4,200+ sqm rsonal use only 4km apart South Granville HQ Auburn freehold ✓ ~2,100 sqm · TGA GMP licensed ✓ ~2,100 sqm · Acquired Nov 2025, $9.5m ✓ Principal cool room capacity +120% ✓ GMP licence variation before the TGA ✓ Secure, monitored 24/7 facility
Slide 7: Track record: Earnings growing faster than revenue
TRACK RECORD Earnings growing faster than revenue rsonal use only Revenue ($m) EBITDA ($m) 16.7 4.3 Q1 FY27 · A record quarter 14.1 $4.6m +17% 12.6 3.4 Revenue 2.8 +18% +27% EBITDA $1.3m +31% +12% +19% EBITDA margin 28.5% +3.1pts Op. cashflow $1.0m +40% FY24 FY25 FY26 FY24 FY25 FY26 Revenue EBITDA E
Slide 8: Growth strategy and catalysts: Converting capacity into growth
GROWTH STRATEGY AND CATALYSTS Converting capacity into growth rsonal use only FY27 STRATEGY NEAR-TERM CATALYSTS 1 Activate Auburn, led by client demand TGA: Auburn facility and release for supply added to GMP licence 2 Accelerate automation and digitisation initiatives Outcome due in coming months 3
Slide 9: Thank you
rsonal use only Thank you Andrew Kerr, Executive Director +61 483 840 860 andrew.kerr@cryosite.com cryosite.com investorhub.cryosite.com